Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
7
×
Tags
life sciences
national blog main
boston blog main
boston top stories
national top stories
biotech
boston
san francisco blog main
san francisco top stories
editas medicine
gene editing
crispr
crispr therapeutics
crispr-cas9
deals
drugs
enzyme
intellia therapeutics
new york blog main
new york top stories
rna
san diego blog main
san diego top stories
san francisco
adeno-associated virus
agios therapeutics
akcea therapeutics
alexandria venture investments
allergan
alnylam pharmaceuticals
altitude life science ventures
american society of gene and cell therapy
arch venture partners
base editing
biopharma
boxer capital
branden moriarty
broad institute
cancer
cas13
What
gene
7
×
medicine
7
×
editing
crispr
therapeutics
therapy
cas
cells
editas
fda
humans
rna
trial
allergan
alnylam
approval
approves
beam
benefit
betting
billion
biopharma
blessing
bosley
cancer
ceo
check
clinical
crude
cusp
cutting
deal
defect
depart
despite
drive
drug
duchenne
edge
edited
Language
unset
Current search:
xconomy.com
×
medicine
×
photo
×
gene
×
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
In Landmark Gene-Editing Study, Sangamo Reports Little Benefit
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com
6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M